2017 Fiscal Year Final Research Report
Development of tumor-specific innovative drug Metformin for gastric cancer cell lines
| Project/Area Number |
15K10008
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
深田 淳一 慶應義塾大学, 医学部(信濃町), 講師 (50338159)
川田 哲也 慶應義塾大学, 医学部(信濃町), 共同研究員 (60234077)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 放射線治療 / 放射線生物学 / 放射線増感剤 / 胃癌 |
|---|
| Outline of Final Research Achievements |
Treatment results of gastric cancer in advanced stages need improvement. More effective anti-tumor radiosensitizing drug is anticipating. We selected metformin which is one of oral diabetes drugs as a promising radiosensitizer. Treatment effectiveness is assessed by irradiation, drug exposure alone and concomitant use of irradiation and drug in human gastric cell lines. Cell survival was evaluated with colony formation. Apoptosis and cell cycle distribution was evaluated using flow cytometric analyses. Combined therapy showed larger cytotoxic effect and higher apoptotic rate than the other exposure. The G2/G1 ratio was elevated and continued in 72-hours by combined therapy. Metformin showed not only cytotoxic effect but radiosensitizing effect in terms of arresting cell cycle in G2/M phase.
|
| Free Research Field |
医学
|
